AZN - AstraZeneca PLC ADR - Stock Forecast

Healthcare - Sector

Coverage Profile Stock analysts Price Targets & Ratings Chart Insider Trading

AZN is currently covered by 10 analysts with an average price target of $117.72. This is a potential upside of $51.46 (77.66%) from yesterday's end of day stock price of $66.26.

AstraZeneca PLC ADR's activity chart (see below) currently has 132 price targets and 124 ratings on display. The stock rating distribution of AZN is 65.38% BUY, 26.92% HOLD and 7.69% SELL.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 42.82% with an average time for these price targets to be met of 357.76 days.

Highest price target for AZN is $95, Lowest price target is $70, average price target is $117.72.

Most recent stock forecast was given by MICHAEL LEUCHTEN from UBS on 20-Nov-2024. First documented stock forecast 14-Oct-2014.

What is AstraZeneca?

AstraZeneca is a biopharmaceutical company that has been at the forefront of discovering, developing, manufacturing, and commercializing prescription medicines since its incorporation in 1992. The company has gained worldwide recognition for its life-saving medicines that millions of people across the globe use. Its headquarters are in Cambridge, UK. The company has a portfolio of products that includes medicines for oncology, cardiovascular diseases, renal diseases, metabolism, respiratory and immunology, and rare diseases.

What made AstraZeneca famous?

AstraZeneca’s commitment to discovering, developing, manufacturing, and commercializing life-saving medicines has made it famous in the biopharmaceutical industry. The company has a robust research and development program that includes partnerships with other companies and research institutions. AstraZeneca’s mission is to improve the health and well-being of people across the world by providing innovative medicines that address unmet medical needs.

What are the famous products or services of AstraZeneca?

Oncology Products

AstraZeneca’s oncology portfolio includes a range of drugs used in the treatment of various types of cancer, including breast cancer, lung cancer, and ovarian cancer. Some of the most well-known products in this category are Tagrisso (osimertinib), Lynparza (olaparib), and Imfinzi (durvalumab)

Cardiovascular, Renal, and Metabolism Products

AstraZeneca’s portfolio of drugs for cardiovascular, renal, and metabolism diseases includes treatments for high blood pressure, high cholesterol, and diabetes. Some of the most well-known products in this category are Brilinta/Brilique (ticagrelor), Brilinta/Brilique (ticagrelor), and Farxiga/Forxiga (dapagliflozin).

Respiratory and Immunology Products

AstraZeneca’s respiratory and immunology portfolio includes treatments for asthma, chronic obstructive pulmonary disease (COPD), and other respiratory diseases. Some of the most well-known products in this category are Symbicort (budesonide/formoterol), Pulmicort (budesonide), and Fasenra (benralizumab).

Rare Disease Products

AstraZeneca’s rare disease portfolio includes treatments for rare genetic disorders. Some of the most well-known products in this category are Soliris (eculizumab) and Ultomiris (ravulizumab)

COVID-19 Products

AstraZeneca has developed and commercialized two COVID-19 vaccines: Vaxzevria and Evusheld. These vaccines have been authorized for emergency use in many countries around the world.

These are just some of the many products that AstraZeneca has developed and commercialized over the years. The company’s portfolio is constantly evolving as new drugs are discovered and approved for use by regulatory agencies around the world.